MedTrace Logo

Slowly Digestible Carbohydrates for GLP-1 Secretion

NCT07572513 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-05-07

No results posted yet for this study

Summary

The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.

Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.

There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:

* Consume a randomized test beverage (SDC or maltodextrin)
* Receive a blood draw at 7 timepoints over 3 hrs
* Take a satiety questionnaire 5 times over 3 hrs
* Consume a standardized lunch 3 hrs after the test beverage consumption

Conditions

  • Blood Glucose
  • GLP-1
  • Satiety
  • Second Meal Intake
  • Healthy Participant Study

Interventions

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit

DIETARY_SUPPLEMENT

Raw Corn Starch

Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).

Sponsors & Collaborators

  • Purdue University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-07-30
Completion
2026-11-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07572513 on ClinicalTrials.gov